SequelSEC

Vera Therapeutics, Inc. VERA

Pharmaceutical Preparations · CIK 0001831828 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2026-06-30
Operating income
-$112.49M
Fiscal year ended 2026-06-30
Free cash flow
-$100.25M
Fiscal year ended 2026-06-30

Vera Therapeutics, Inc. (VERA) reported net income of -$109.47M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Vera Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Vera Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
RevenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$112.49MUnavailable-$94.21M-$83.93MUnavailableUnavailable-$48.91M-$49.80MUnavailableUnavailable
Net income-$109.47MUnavailable-$91.10M-$80.29MUnavailableUnavailable-$43.42M-$46.63MUnavailableUnavailable
Research & development$60.08MUnavailable$59.31M$56.47MUnavailableUnavailable$33.35M$40.31MUnavailableUnavailable
Weighted-average diluted sharesshares 71.84MUnavailableUnavailableshares 63.85MUnavailableUnavailableUnavailableshares 54.90MUnavailableUnavailable
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expenseUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Diluted EPS$-1.52UnavailableUnavailable$-1.26UnavailableUnavailableUnavailable$-0.85UnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$52.41MUnavailable$34.90M$27.46MUnavailableUnavailable$15.57M$9.49MUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Vera Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Cash & equivalents$48.88MUnavailable$354.72M$57.77MUnavailableUnavailable$92.65M$27.26MUnavailableUnavailable
Total assets$532.98MUnavailable$734.73M$517.50MUnavailableUnavailable$655.68M$368.56MUnavailableUnavailable
Current assets$527.49MUnavailable$728.88M$511.31MUnavailableUnavailable$651.22M$364.13MUnavailableUnavailable
Total liabilities$125.23MUnavailable$130.21M$118.62MUnavailableUnavailable$78.53M$79.50MUnavailableUnavailable
Current liabilities$48.32MUnavailable$53.46M$41.88MUnavailableUnavailable$25.37M$26.46MUnavailableUnavailable
Total equity incl. NCI$407.76MUnavailable$604.52M$398.88MUnavailableUnavailable$577.16M$289.06MUnavailableUnavailable
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt$75.23MUnavailable$74.84M$74.65MUnavailableUnavailable$50.69M$50.47MUnavailableUnavailable
Accounts payable$14.57MUnavailable$21.90M$17.95MUnavailableUnavailable$7.66M$4.60MUnavailableUnavailable

Cash flow

Vera Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Operating cash flow-$100.25MUnavailable-$69.99M-$61.91MUnavailableUnavailable-$39.18M-$36.88MUnavailableUnavailable
Capital expenditures$0Unavailable$102.00K$133.00KUnavailableUnavailable$645.00K$238.00KUnavailableUnavailable
Investing cash flow$32.86MUnavailable$80.66M$69.76MUnavailableUnavailable-$221.38M$38.32MUnavailableUnavailable
Financing cash flow$1.92MUnavailable$286.28M$797.00KUnavailableUnavailable$325.96M$739.00KUnavailableUnavailable
Net change in cash-$65.48MUnavailable$296.95M$8.65MUnavailableUnavailable$65.39M$2.17MUnavailableUnavailable
Stock-based compensation$15.86MUnavailable$10.96M$9.74MUnavailableUnavailable$6.22M$5.59MUnavailableUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailable$0UnavailableUnavailableUnavailable$0UnavailableUnavailableUnavailable
Depreciation & amortization$132.00KUnavailable$135.00K$129.00KUnavailableUnavailable$55.00K$24.00KUnavailableUnavailable

Derived

Vera Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Free cash flow-$100.25MUnavailable-$70.10M-$62.04MUnavailableUnavailable-$39.83M-$37.12MUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio10.92xUnavailable13.64x12.21xUnavailableUnavailable25.67x13.76xUnavailableUnavailable
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equity0.18xUnavailable0.12x0.19xUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open VERA in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-10View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-02-26View SEC filing
10-Q · Filed 2025-11-05View SEC filing
10-Q · Filed 2025-08-05View SEC filing
10-Q · Filed 2025-05-07View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Reconciliation checks needing review

14 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

gross profit bridgeinconsistent2026-03-31

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2026-03-31

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2025-06-30

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2025-06-30

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2025-03-31

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2025-03-31

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2024-06-30

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2024-06-30

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2024-03-31

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2024-03-31

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2023-06-30

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2023-06-30

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.